Over the past several decades the cure rate for children with cancer has increased, but those children withtherapy-resistant disease are still in need of new treatment approaches. One such strategy involves targetingthe vasculature upon which tumor growth and spread are dependent. Angiogenesis inhibitors are alreadybeing introduced into the clinic for the treatment of children with solid tumors, often in combination withadjuvant therapy including chemotherapeutic drugs and ionizing radiation. However, no rational guidelinesexist to assist the clinician in determining the optimal dosing and scheduling for angiogenesis inhibitors,particularly in pediatric patients. The overriding hypothesis of this proposal is that through an improvedunderstanding and monitoring of the phenotypic and functional changes in the tumor vasculature effected byangiogenesis inhibitors, significant improvements in the antitumor efficacy of conventional cytotoxic agentscan be achieved for the treatment of children with solid malignancies. We plan to use orthotopic pediatricxenografts to 1) assess the potential of noninvasive imaging modalities to accurately and reliably evaluatechanges in the tumor vasculature in response to anti-angiogenic therapy, 2) determine the optimal treatmentschedule of therapy that combines anticancer drugs with angiogenesis inhibitors, based on an understandingof the mechanism and timing of tumor vessel response to anti-angiogenic agents, 3) determine the effectthat anti-angiogenic agents have on the expression and function of drug export and resistance proteins, and4) devise a model based on pharmacokinetic and pharmacodynamic data that will predict the optimal use ofanti-angiogenic agents for pediatric patients with solid malignancies. The results of our studies have greatpotential to contribute to the rational use of angiogenesis inhibitors in the treatment of children with solidtumors.
Showing the most recent 10 out of 814 publications
